Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Align probiotic goes national

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble's patented probiotic dietary supplement Align reaches store shelves in its nationwide launch, the firm announces May 12. The trademarked bacterial strain in the product, Bifantis, is "clinically proven to help promote the balance of healthy bacteria in the digestive system and to help build and maintain an ongoing natural defense against the five signs of episodic digestive imbalance - constipation, diarrhea, urgency, gas and bloating," the firm says. A 28-count bottle of the once-daily product retails for approximately $30. P&G licenses Bifantis from Irish specialty biotech firm Alimentary Health. P&G holds the trademark and has patent protection until 2020. Marketing initiatives to support the launch include partnering with "celebrity nutritionist" Ashley Koff in an essay contest about consumers' digestive health at 1www.MyDigestiveMakeover.com (2"The Tan Sheet" April 20, 2009, p. 17)

You may also be interested in...



Brands Strain To Stand Out In Probiotic Competition

Major brands are stocking retail shelves with dietary supplements containing probiotic bacteria, but the firms face a growing challenge for making their bacterial strains stand out from the competition

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Topics

UsernamePublicRestriction

Register

PS102907

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel